Neuroendocrinology News
-
Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will present at the H.C. Wainwright Virtual BIOCONNECT Conference being held January 10-13, 2022. A webcast of the presentation will be available at 7:00AM ET on January 10th through the following link: ...
By Lumos Pharma
-
Pronalyse’s Fusion Protein Characterization Service Aids in the Drug Development Process
Pronalyse is a subdivision of Creative Proteomics, an integrated CRO company with rich experience in providing drug development services. Building on its years of experience, Creative Proteomics Pronalyse announces the launch of its fusion proteins characterization service to ensure the production of safe and effective therapeutic fusion proteins. Fusion protein refers to a new type of synthetic ...
-
Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on rare endocrine disorders, announced that the Company will host two key opinion leaders in the field of pediatric endocrinology for a discussion of interim data from our Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials evaluating oral LUM-201 in Pediatric Growth Hormone Deficiency (PGHD). The KOL webinar will ...
By Lumos Pharma
-
Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference
Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present and host one-on-one meetings at the Piper Sandler 34th Annual Healthcare Conference November 29th through December 1st. Event: Piper Sandler 34th Annual ...
By Lumos Pharma
-
Juvena Therapeutics Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases
Juvena Therapeutics, Inc. (“Juvena”), a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, announced today that it has raised $41 million in an oversubscribed Series A, bringing its total funding to $50 million. The new funding will power the expansion of Juvena’s drug discovery platform and advance the company’s ...
-
Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference
Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that Lumos Pharma management will participate in a panel discussion and host one-on-one meetings at the Cantor Neurology & Psychiatry Conference in October. Event: Cantor Neurology ...
By Lumos Pharma
-
Lumos Pharma Announces Share Repurchase Program
Lumos Pharma, Inc. (“The Company,” NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), today announced that its board of directors has authorized a share repurchase program to acquire up to $3 million of the Company’s common stock. The Company may purchase ...
By Lumos Pharma
-
Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, initially targeting pediatric growth hormone deficiency, today announced a collaboration with Laura Dichtel, MD of Massachusetts General Hospital to evaluate the orally administered growth hormone (GH) secretagogue, LUM-201, in Nonalcoholic Fatty Liver Disease (NAFLD). The ...
By Lumos Pharma
-
Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD
Interim Data Anticipated by End of 2022 - Interim Data from PK/PD OraGrowtH212 Trial also Anticipated by End of 2022 - Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced this morning achievement of the 50% randomization milestone for our Phase 2 OraGrowtH210 Trial evaluating orally administered LUM-201 in ...
By Lumos Pharma
-
Lumos Pharma to Participate in the Cantor Rare Disease Symposium
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that John McKew, PhD, President and Chief Scientific Officer of Lumos Pharma, will participate in a panel discussion at the Cantor Rare Disease Symposium at the end of March 2022. Event: Cantor Rare Disease Symposium – March 28-30 Presentation: Panel ...
By Lumos Pharma
-
EsoCap announces first patient enrolled in Phase II eosinophilic esophagitis trial
Randomized, placebo-controlled, double-blind Phase II trial to treat 42 patients ongoing in four European countries with ESO-101 ESO-101, EsoCap’s lead product candidate, consists of a capsule with a rolled, thin mucoadhesive film, loaded with the anti-inflammatory corticosteroid, mometasone furoate In a previous trial, EsoCap’s proprietary and unique targeted application ...
By EsoCap AG
-
Lumos Pharma Announces OraGrowtH212 Trial of LUM-201 in PGHD Is Open for Enrollment
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that the OraGrowtH212 Trial, a Phase 2 PK/PD study of the company’s lead asset LUM-201 for the treatment of patients with pediatric growth hormone deficiency (PGHD), is open for enrollment. Lumos Pharma believes an increase in the pulsatile release of ...
By Lumos Pharma
-
Reduce antibiotic use in farming
To round off World Antibiotic Awareness Week in November, the Alliance to Save our Antibiotics have produced a report calling for Government to protect public health and take a stronger stance against using antibiotics too much on farms. The US, Australia, New Zealand and Canada, which are all in trade negotiations with the UK, allow farmers to give antibiotics to livestock to make them grow ...
-
Agilent Technologies presents 2011 manfred donike award for excellence in sports-doping detection to german and swiss researchers
Agilent Technologies, Inc. (NYSE: A) today announced it has presented the 2011 Manfred Donike Award for scientific excellence in sports-doping testing to Simon Beuck and Nicolas Leuenberger. Agilent sponsors this annual award to recognize distinguished scientific contributions in doping analysis. Award winners are scientists who exemplify the spirit and scientific leadership of doping control ...
-
ReportAlert.info - Novo Nordisk (CPH:NOVO.B) publishes 2010 annual report
Novo Nordisk, the world leader in diabetes care, has released its seventh annual integrated report with 2010 results. The company’s achievements for the year include solid sales growth, progress in clinical development programmes, healthcare system capacity building, and reductions in resource consumption and CO2 emissions. During 2010, Novo Nordisk: Increased sales by 13% (in local ...
By 3BL Media
-
LOHAS 2010 forum insights: `cultural shifts from me to we`; `boycotting BP knee-jerk reaction`; `hedonics and economics`; `killing kids with food`; `values are social currency`; `global LOHAS`
LOHAS (acronym for Lifestyles of Health and Sustainability) wrapped last Friday afternoon, following three days of insightful panels and networking opportunities attended by thought leaders across industries, government, non-profit organizations, research organizations and academic institutions including Faith Popcorn, Joel Makower, Dr. Alan Greene, Philippe Cousteau, U.S. EPA"s Stephanie Owens, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you